Exemestane
Adjuvant treatment of post menopausal women with estrogen-positive early breast cancer who have received tamoxifen therapy for 2-3 years and are switched to exemestane for completion of a total of 5 consecutive years of adjuvant hormonal therapy. Treatment of advanced breast cancer in post menopausal women whose disease has progressed even after following tamoxifen therapy
Early and advanced breast cancer 25mg; but for patients receiving exemestane with a potent CYP3A4 inducer 50mg orally once daily after meal.
Moderate or sever hepatic or renal impairment. Pregnancy.
Osteoporosis, Liver disease, kidney disease.
Hot flashes, nausea, fatigue, increase in tumor size, depression, allergic reaction.
CyP3A4 inducer such as rifampicin or phenytoin.
